PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer

This study (called PROMOTE) is trying to predict which patients with advanced or recurring uterine (endometrial) cancer will respond to hormonal therapy, by analyzing tumor tissue samples taken before treatment begins. **You may be eligible if...** - You have been diagnosed with advanced (stage III or IV) or recurrent endometrial cancer (cancer of the lining of the uterus) - You are planned to receive any type of hormonal therapy as your treatment - A tumor biopsy was taken within 120 days before starting hormonal therapy - No other cancer treatment was given between the biopsy and starting hormonal therapy **You may NOT be eligible if...** - Your cancer has been completely surgically removed and hormonal therapy is only used as a preventive measure - You are using hormonal therapy for another reason unrelated to cancer - You have been diagnosed with a uterine sarcoma (a different type of uterine cancer) Talk to your doctor to see if this trial is right for you.